GlaxoSmithKline (NYSE: GSK) is expected to report Q3 earnings on Oct. 31. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict GlaxoSmithKline's revenues will decrease -2.0% and EPS will grow 4.5%.

The average estimate for revenue is $10.89 billion. On the bottom line, the average EPS estimate is $0.92.

Revenue details
 Last quarter, GlaxoSmithKline chalked up revenue of $10.14 billion. GAAP reported sales were 6.1% lower than the prior-year quarter's $10.79 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $0.82. GAAP EPS of $0.39 for Q2 were 11% higher than the prior-year quarter's $0.35 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 72.4%, 230 basis points worse than the prior-year quarter. Operating margin was 30.9%, 120 basis points better than the prior-year quarter. Net margin was 19.4%, 290 basis points better than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $43.46 billion. The average EPS estimate is $3.68.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 31 members out of 35 rating the stock outperform, and four members rating it underperform. Among three CAPS All-Star picks (recommendations by the highest-ranked CAPS members), three give GlaxoSmithKline a green thumbs-up, and give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on GlaxoSmithKline is outperform, with an average price target of $48.52.